Abstract
Drug delivery in ocular therapeutics is a challenging problem and is a subject of interest to scientists working in the multidisciplinary areas pertaining to the eye. Most ocular diseases are treated by topical drug application in the form of solutions, suspensions and ointment. These conventional dosage forms suffer from the problems of poor ocular bioavailability, because of various anatomical and pathophysiological barriers prevailing in the eye. Various efforts in ocular drug delivery have been made to improve the bioavailability and to prolong the residence time of drugs applied topically onto the eye. The potential use of polymeric nanoparticles as drug carriers has led to the development of many different colloidal delivery vehicles. Indeed, the association of an active molecule to a nanocarrier allows the molecule to intimately interact with specific ocular structures, to overcome ocular barriers and to prolong its residence in the target tissue. This review discusses the physiochemical characterization, fabrication techniques, therapeutic significances, patented technology of Eudragit based nanoparticles and future possibility in the field of ocular drug delivery.
References
Eva del Amo, M.; Urtti, A. Current and Future Ophthalmic Drug Delivery Systems: A Shift to the Posterior Segment. Drug Discovery Today. 2008, 13, 135–143.
A. Topalkara, C. Gu¨ ler, D.S. Arici, M.K. Arici, Adverse effects of topical antiglaucoma drugs on the ocular surface, Clin. Exp. Ophthalmol. 28 (2000) 113– 117.
S.K. Sahoo, F. Dilnawaz, S. Krishnakumar, Nanotechnology in ocular drug delivery, Drug Discov. Today 13 (2008) 144–150.
M. Hamidi, A. Azadi, P. Rafiei, Hydrogel nanoparticles in drug delivery, Adv. Drug Deliv. Rev. 60 (2008) 1638–1649.
P. Calvo, C. Remuñán-López, J.L. Vila-Jato, M.J. Alonso, Novel hydrophilic chitosan–polyethylene oxide nanoparticles as protein carriers, J. Appl. Polym. Sci. 63 (1997) 125–132.
Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002;16:53Y61.
A. Urtti, L. Salminen, Minimizing systemic absorption of topically administered ophthalmic drugs, Surv. Ophthalmol. 37 (1993) 435–457.
H.S. Huang, R.D. Schoenwald, J.L. Lach, Corneal penetration behavior of beta-blockers, J. Pharm. Sci. 72 (1983) 1272–1279.
M. Hornof, E. Toropainen, A. Urtti, Cell culture models of the ocular barriers, Eur. J. Pharm. Biopharm. 60 (2005) 207–225.
D.H. Geroski, H.F. Edelhauser,Drug delivery for posterior segment eye disease, Investig.Ophthalmol.Vis. Sci. 41 (5) (2000) 961–964.
T.F. Patton, J.R. Robinson, Ocular evaluation of polyvinyl alcohol vehicle in rabbits, J. Pharm. Sci. 64 (1975) 1312–1316.
I.P. Kaur, R. Smitha, Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery, Drug Dev. Ind. Pharm. 28 (2002) 353–369.
A. Ludwig, The use of mucoadhesive polymers in ocular drug delivery, Adv. Drug Deliv. Rev. 57 (2005) 1595–16.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array